Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004830-81
    Sponsor's Protocol Code Number:FIL_BArT
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-004830-81
    A.3Full title of the trial
    A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C virus-associated indolent B-cell lymphomas
    Studio multicentrico per valutare l’attività antivirale di un trattamento senza interferone con ledipasvir più sofosbuvir (genotipi 1 e 4) e sofosbuvir più velpatasvir (genotipi 2 e 3) in pazienti affetti da linfoma indolente a cellule B associato ad infezione da virus dell’epatite C
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C virus-associated indolent B-cell lymphomas
    Studio multicentrico per valutare l’attività antivirale di un trattamento senza interferone con ledipasvir più
    sofosbuvir (genotipi 1 e 4) e sofosbuvir più velpatasvir (genotipi 2 e 3) in pazienti affetti da linfoma indolente a cellule B associato ad infezione da virus dell’epatite C
    A.3.2Name or abbreviated title of the trial where available
    FIL_BArT (B-cell Lymphoma Antiviral Treatment BArT study)
    FIL_BArT (B-cell Lymphoma Antiviral Treatment BArT study)
    A.4.1Sponsor's protocol code numberFIL_BArT
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN00000000
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02836925
    A.5.4Other Identifiers
    Name:FIL_BArTNumber:FIL_BArT
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorFONDAZIONE ITALIANA LINFOMI ONLUS
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGilead Science S.r.l
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationFondazione Italiana Linfomi Onlus
    B.5.2Functional name of contact pointUffici Studi FIL
    B.5.3 Address:
    B.5.3.1Street AddressSpalto Marengo 44 c/o Uffici PACTO
    B.5.3.2Town/ cityAlessandria
    B.5.3.3Post code15121
    B.5.3.4CountryItaly
    B.5.4Telephone number0131033151
    B.5.5Fax number0131263455
    B.5.6E-mailsegreteria@filinf.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 3 FLACONI 3X28 COMPRESSE RIVESTITE CON FILM
    D.2.1.1.2Name of the Marketing Authorisation holderGILEAD SCIENCES INTERNATIONAL LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLedipasvir/Sofosbuvir
    D.3.2Product code [Harvoni]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsofosbuvir
    D.3.9.1CAS number 1190307-88-0
    D.3.9.2Current sponsor codeSofosbuvir
    D.3.9.4EV Substance CodeSUB121170
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNledipasvir
    D.3.9.1CAS number 1256388-51-8
    D.3.9.2Current sponsor codeledipasvir
    D.3.9.4EV Substance CodeSUB120165
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name EPCLUSA - 400 MG/100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 28 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderGILEAD SCIENCES INTERNATIONAL LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSofosbuvir/Velpatasvir
    D.3.2Product code [Epclusa]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSofosbuvir
    D.3.9.1CAS number 1190307-88-0
    D.3.9.2Current sponsor codeSofosbuvir
    D.3.9.4EV Substance CodeSUB121170
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVelpatasvir
    D.3.9.1CAS number 1377049-84-7
    D.3.9.2Current sponsor codeVelpatasvir
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with hepatitis C virus-associated indolent B-cell lymphomas
    Pazienti affetti da linfoma indolente a cellule B associato ad infezione da virus dell’epatite C
    E.1.1.1Medical condition in easily understood language
    Patients with hepatitis C virus-associated indolent B-cell lymphomas
    Pazienti affetti da linfoma indolente a cellule B associato ad infezione da virus dell’epatite C
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level PT
    E.1.2Classification code 10065856
    E.1.2Term Non-Hodgkin's lymphoma unspecified histology indolent
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10065051
    E.1.2Term Acute hepatitis C
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • Virological: to evaluate the efficacy of interferon-free regimens to eradicate HCV infection in patients with indolent B-cell lymphoma
    • Virologico: valutare l'efficacia di regimi senza interferone per eradicare l'infezione da HCV nei pazienti affetti da linfoma non Hodgkin indolente a cellule B
    E.2.2Secondary objectives of the trial
    • Hematological: to investigate the efficacy of interferon-free regimens on complete or partial regression of HCV-associated indolent B-cell lymphoma
    • Hematological: to investigate the freedom from progression of disease and the survival probability in patients with HCV-associated indolent B-cell lymphoma
    • Virological: to investigate on-treatment virological response and non-response
    • Safety of treatment
    • Ematologico: indagare l'efficacia di regimi senza interferone nel determinare la regressione completa o parziale del linfoma indolente a cellule B associato ad infezione da virus dell’epatite C
    • Ematologico: indagare la PFS e il tasso di sopravvivenza in pazienti affetti da linfoma indolente a cellule B associato ad infezione da virus dell’epatite C
    • Virologico: indagare la risposta e la non risposta virologica nel corso del trattamento
    • Sicurezza del trattamento
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Age >18 years
    2. Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular lymphoma grade 1 and 2, CD5-negative B-cell lymphoma NOS
    3. HCV-RNA positivity
    4. Assessable HCV genotype
    5. No previous therapy for the lymphoma
    6. 6. Measurable disease after diagnostic biopsy (longest axis =1.5 cm for nodal and =1 cm for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and =5 x 109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in CD5-negative B-cell lymphoma NOS)
    7. No need of immediate lymphoma treatment defined as absence of all the following criteria: systemic symptoms, bulky nodal or extranodal mass (>7 cm), symptomatic splenomegaly, progressive leukemic phase, serous effusions
    8. Performance status <2 according to ECOG scale
    9. Adequate hematological counts: ANC >1 x 109/L, hemoglobin >9 g/dl (transfusion independent), platelet count > 50 x 109/L (transfusion independent)
    10. No central nervous system (CNS) disease (meningeal and/or brain involvement by lymphoma)
    11. Adequate kidney function (creatinine clearance = 45 ml/min)
    12. Cardiac ejection fraction =45% (echocardiography or MUGA scan)
    13. Normal lung function
    14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS
    15. Non major surgical intervention prior 3 months to enrolment if not due to lymphoma and/or no other disease life-threatening that can compromise chemotherapy treatment
    16. Disease free of prior malignancies other than lymphoma for >3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
    17. Life expectancy > 6 months
    18. No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
    19. Written informed consent
    20. Women must be:
    - postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
    - surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
    - completely abstinent (at the discretion of the investigator/per local regulations) (periodic abstinence from intercourse is not permitted) or
    - if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment.
    21. Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
    22. Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 1 month after receiving the last dose of study drug
    1. Età >18 anni
    2. Linfoma indolente a cellule B (linfoma della zona marginale – nodale, extranodale, splenico, e diffuso - linfoma linfoplasmacitico, linfoma linfocitico a piccole cellule B, linfoma follicolare di grado 1 e 2, linfoma a cellule B CD5 negativo NOS)
    3. Positività HCV-RNA
    4. Genotipo HCV valutabile
    5. Nessuna terapia precedente per il linfoma
    6. Malattia misurabile dopo la biopsia diagnostica (asse più lungo =1,5 cm per le lesioni nodali e =1 cm per le lesioni extranodali) e/o malattia valutabile (infiltrazione midollare quantificabile e cellule B clonali nel sangue periferico =5 x 109/l, in caso di mancata infiltrazione midollare/leucemizzazione in linfoma a cellule B CD5 negativo NOS
    7. Il paziente non necessita un trattamento immediato per il linfoma, definito come l’assenza di tutti i seguenti criteri: sintomi sistemici, massa bulky nodale o extranodale (>7cm), splenomegalia sintomatica, progressiva leucemizzazione, effusioni sierose
    8. ECOG Performance status <2
    9. Adeguata conta ematologica: ANC > 1 x 109/L, emoglobina >9 g/dl (trasfusione indipendente), adeguata conta piastrinica >50x109/L (trasfusione indipendente)
    10. Assenza di patologie del SNC (interessamento delle meningi e /o del cervello da parte del linfoma)
    11. Adeguata funzionalità renale (clearance della creatinina = 45 ml/min)
    12. Frazione di eiezione =45% (misurata con ecocardiografia o MUGA scan)
    13. Funzionalità polmonare normale
    14. Assenza di neuropatia periferica o patologia attiva neurologica non neoplastica del SNC
    15. Assenza di interventi chirurgici importanti nei 3 mesi predenti all’arruolamento, se non dovuti al linfoma e/o assenza di altre patologie che possano portare alla morte o compromettere il trattamento chemioterapico
    16. Assenza di precedenti tumori diversi dal linfoma da più di 3 anni, ad eccezione del carcinoma della pelle a cellule squamose e a cellule basali, attualmente curato, o carcinoma in situ della cervice o della mammella
    17. Aspettativa di vita > 6 mesi
    18. Assenza di patologie psichiatriche che precludano la comprensione dei contenuti dello studio o la firma del Consenso Informato
    19. Firma del consenso informato
    20. Le pazienti di sesso femminile devono:
    • essere in post-menopausa da almeno 1 anno (assenza di mestruazione spontanea da almeno 12 mesi)
    • essere chirurgicamente sterili (isterectomia od ovariectomia bilaterale, chiusura delle tube, o impossibilità di rimanere incinta)
    • osservare astinenza totale (a discrezione dello sperimentatore/in base ai regolamenti locali) (l’astinenza periodica dai rapporti sessuali non è consentita) o
    • se sessualmente attive, utilizzare un metodo di controllo delle nascite efficace (es. prescrizione di contraccettivi orali, iniezioni o cerotto, dispositivo intrauterino, metodo contraccettivo di doppia barriera (profilattico, diaframma o cappuccio cervicale, con spermicida – crema, gel o schiuma – partner sterile) in conformità alle norme locali, prima dell’ingresso in studio, e devono continuare ad utilizzare lo stesso metodo contraccettivo nel corso dello studio. Le pazienti devono inoltre continuare ad utilizzare metodi di controllo delle nascite per almeno 6 mesi dal termine del trattamento.
    21. Le donne in età fertile devono ottenere, in fase di screening, un test di gravidanza negativo (test beta-hCG – beta-human chronic gonadotropin - su siero o urina)
    22. I pazienti di sesso maschile devono utilizzare un metodo di controllo delle nascite accettabile per tutta la durata dello studio. Devono utilizzare un metodo contraccettivo di doppia barriera e non donare lo sperma nel corso dello studio e nel mese successivo all’ultima dose del farmaco
    E.4Principal exclusion criteria
    1. Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma
    2. Previous anti-HCV treatment with sustained virological response
    3. Diagnosis of cirrhosis (histological or Stiffness >12 KpA)
    4. CNS disease (meningeal and/or brain involvement by lymphoma)
    5. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
    6. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)
    7. Concomitant therapy with amiodarone
    8. Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
    9. Cardiac ejection fraction <45% (MUGA scan or echocardiography).
    10. Creatinine clearance <45 ml/min
    11. Presence of major neurological disorders
    12. HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+, HbsAg-, HBsAb+/- patients with HBV-DNA negativity
    13. Ongoing systemic bacterial, fungal or viral infections at the time of initiation of study treatment (defined as requiring therapeutic dosing of an antimicrobial, antifungal or antiviral agent)
    14. Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or other
    15. Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
    16. Life expectancy <6 months
    17. Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
    18. If female, the patient is pregnant or breast-feeding.
    1. Diagnosi di linfoma linfoblastico, Burkitt, diffuso a grandi cellule B, mantellare, follicolare di grado 3, primitivo del mediastino
    2. Trattamento precedente anti HCV con risposta virologica sostenuta
    3. Diagnosi di cirrosi (istologica o Stiffness > 12 KpA)
    4. Patologia del SNC (interessamento delle meningi e /o del cervello da parte del linfoma)
    5. Anamnesi di insufficienza epatica o renale clinicamente rilevante; significativi disturbi cardiaci, vascolari, polmonari, gastrointestinali, dell’apparato endocrino, neurologici, reumatologici, ematologici, psichiatrici o metabolici
    6. Diabete non controllato (se il paziente assume antidiabetici, il dosaggio di tali farmaci deve essere stabile da almeno 3 mesi prima dell’inizio della terapia prevista da protocollo)
    7. Terapie concomitanti con amiodarone
    8. Patologia cardiovascolare non controllata o grave, incluso infarto del miocardio nei 6 mesi precedenti all’arruolamento, insufficienza cardiaca di classe III o IV (New York Heart Association - NYHA), angina non controllata
    9. Frazione di eiezione cardiaca <45% (MUGA scan o ecocardiografia)
    10. Clearance della creatinina <45 ml/min
    11. Importanti disturbi neurologici
    12. Positività a HIV, HBV (HbsAg+ o HBV-DNA+) ad eccezione di pazienti HBV-DNA negativi (HBcAb+, HbsAg-, HBsAb+/-)
    13. Infezioni sistemiche batteriche, fungine o virali in corso al momento dell’arruolamento (che necessitano una terapia con agenti antimicrobici, antifungini o antivirali)
    14. Interventi chirurgici importanti nei 3 mesi predenti all’arruolamento, se non dovuti al linfoma e/o altre patologie
    15. Precedenti tumori diversi dal linfoma negli ultimi 3 anni, ad eccezione del carcinoma della pelle a cellule squamose e a cellule basali, o carcinoma in situ della cervice o della mammella
    16. Aspettativa di vita <6 mesi
    17. Qualsiasi condizione clinica o psicologica che possa precludere la partecipazione allo studio o compromettere la capacità di firmare il consenso
    18. Gravidanza o allattamento per le pazienti di sesso femminile
    E.5 End points
    E.5.1Primary end point(s)
    Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy
    • Virologico: Proporzione di pazienti con SVR12 al termine del trattamento. SVR12 o Risposta Virologica Sostenuta (SVR12), è definita come negatività dell'HCV-RNA (dosaggio al di sotto limite di rilevamento, 15IU/ml) a 12 settimane dalla conclusione del trattamento antivirale
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 weeks from the end of treatment
    12 settimane dalla fine del trattamento
    E.5.2Secondary end point(s)
    • Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction. Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions. Lymphoma response will be assessed 12 weeks after the end of antiviral treatment; PFS; Event-free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause; Overall survival (OS) defined as the time between enrolment and death from any cause; Rate of virological response
    Ematologico: Tasso di risposta globale (ORR), ovvero la proporzione di risposte complete (CR) e di risposte parziali (PR) secondo i criteri di Cheson 2014, valutato a 12 settimane dal termine del trattamento; Progression Free Survival (PFS) definita come l’intervallo di tempo tra la data di arruolamento del paziente e la data di progressione o recidiva o morte per qualsiasi causa. ; Event Free Survival (EFS) definita come l’intervallo di tempo tra la data di arruolamento del paziente e la data di interruzione del trattamento per qualsiasi causa (progressione, tossicità, scelta del paziente, inizio di un nuovo trattamento senza progressione documentata, decesso); Overall Survival (OS) definita come l’intervallo di tempo tra la data di arruolamento del paziente e la data di decesso per qualsiasi causa; Risposta virologica
    E.5.2.1Timepoint(s) of evaluation of this end point
    12 weeks from the end of treatment; 36 months; 36 months; 36 months; 4 weeks
    12 settimane dalla fine del trattamento; 36 mesi; 36 mesi; 36 mesi; 4 settimane
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned21
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 44
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state44
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 44
    F.4.2.2In the whole clinical trial 44
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Restaging phase: 12 weeks after the conclusion of antiviral treatment patients will undergo to HCV-RNA testing to detect viral response (SVR12). At the same time-point a complete lymphoma restaging will be performed.
    Follow up phase : After antiviral therapy completion and restaging
    phase patients will be evaluated for SVR, safety, ORR and vital status every 3 months for 1 year and then every 6 months for 2 years.
    Restaging: 12 settimane dopo la conclusione del trattamento antivirale, sarà effettuato il test HCV-RNA per la valutazione della risposta virologica (SVR 12). Nello stesso time-point, sarà eseguita una rivalutazione completa del linfoma.
    Follow-up: dopo il completamento della terapia antivirale e dopo la fase di restaging, i pazienti saranno valutai per la SVR, l'ORR e per i parametri vitali ogni 3 mesi per 1 anno e successivamente ogni 6 mesi per 2 anni.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-12-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-11-23
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-11-17
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:47:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA